Helus Pharma announces upcoming milestones, catalysts

The company said, “HLP004 Phase 2 Program in Generalized Anxiety Disorder: Anticipated topline data readout from the Phase 2 study evaluating HLP004 in GAD in Q1 2026. HLP003 Phase 3 Program in Major Depressive Disorder: Continued execution of the APPROACH pivotal Phase 3 study evaluating HLP003 as an adjunctive treatment for MDD with topline data anticipated in Q4 2026. Continued execution of the EMBRACE complementary Phase 3 study, which initiated patient enrollment in the prior quarter, designed to reinforce efficacy findings and support the overall evidence package for HLP003 in MDD. Ongoing patient participation in the EXTEND long-term extension study, supporting the collection of long-term safety and durability data.”